Rise to the challenge

Median OS (dual primary endpoint): 18.6 months with DATROWAY and 18.3 months with chemotherapy (HR=1.01; 95% CI: 0.83, 1.22). Data was not statistically significant.1

aTROPION-Breast01 had dual primary endpoints of PFS (BICR) and OS (see below for summary of study design). The study was positive if either PFS or OS results were statistically significant.1,6

TROPION-Breast01: A multicenter, open-label, randomized phase 3 trial of DATROWAY (6 mg/kg IV Q3W) vs investigator’s choice of chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in 732 previously treated patients with unresectable or metastatic HR+/HER2− breast cancer. Patients must have progressed on and deemed not suitable for further endocrine therapy, and received 1 or 2 lines of prior chemotherapy in the unresectable or metastatic disease setting. Stratification factors included 1 or 2 previous lines of chemotherapy, prior CDK4/6 inhibitor use, and geography. Dual primary endpoints were PFS (BICR) and OS.1,2